SCHEMBL4700809

SCHEMBL4700809

O=C1C[C@@H](NS(=O)(=O)c2ccc(Oc3ccc(F)cc3)cc2)C(=O)N1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.45
MMP9 P14780 10/20 0.45
AR P10275 1/20 0.45
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
F10 P00742 1/20 0.43
MMP13 P45452 5/20 0.40
MMP14 P50281 4/20 0.40
HTR1A P08908 2/20 0.40
HTR7 P34969 2/20 0.40
MMP3 P08254 2/20 0.40
MMP1 P03956 1/20 0.40
MMP7 P09237 1/20 0.40
KCNA5 P22460 1/20 0.40
NR3C1 P04150 1/20 0.40
DRD2 P14416 1/20 0.39
HTR6 P50406 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
UCHL1 P09936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702692 0.94 MMP2 (0.46) MMP2MMP9ARFFAR1FFAR4
SCHEMBL5882183 0.85 F10 (0.44) MMP2MMP9F10MMP13MMP14
SCHEMBL5882266 0.83 ALDH1A1 (0.44) MMP9ARMMP13MMP3MMP1
SCHEMBL4698153 0.82 F10 (0.51) MMP2MMP9ARFFAR1FFAR4
SCHEMBL4698155 0.82 F10 (0.51) MMP2MMP9ARFFAR1FFAR4
SCHEMBL4698467 0.80 F10 (0.42) MMP2MMP9F10MMP13MMP14
Hydrochloric Acid SCHEMBL4703963 0.79 F10 (0.42) MMP2MMP9F10MMP13MMP14
SCHEMBL4699851 0.79 MMP13 (0.42) MMP2MMP9MMP13MMP3MMP1
SCHEMBL4756093 0.77 MMP2 (0.50) MMP2MMP9FFAR1FFAR4MMP13
SCHEMBL14040537 0.77 MMP2 (0.50) MMP2MMP9FFAR1FFAR4MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1444202-B1 NOVEL METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2008-10-15 EP disclosed
US-7132434-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2006-11-07 US disclosed
US-20050026990-A1 Novel metalloproteinase ihibitors ASTRAZENECA AB (SE) 2005-02-03 US disclosed
EP-1444202-A1 NOVEL METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2004-08-11 EP disclosed
WO-2003040098-A1 NOVEL METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026990-A1 Novel metalloproteinase ihibitors MMP12, MMP1, MMP16 MMP2 12/4885MMP9 14/4885AR 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.